Marta Novella-Navarro
Overview
Explore the profile of Marta Novella-Navarro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Novella-Navarro M, Van Den Rym A, Lopez-Pedrera C, Martinez-Feito A, Nieto-Carvalhal B, Reche K, et al.
Nutrients
. 2025 Mar;
17(5).
PMID: 40077690
: Obesity is a frequent comorbidity in rheumatoid arthritis (RA). This condition may lead these patients to have poorer disease control and a worse response to some of the available...
2.
Calvo-Aranda E, Barrio Nogal L, Blanco Caceres B, Peiteado D, Novella-Navarro M, De Miguel E, et al.
Nefrologia (Engl Ed)
. 2024 Nov;
44(6):877-884.
PMID: 39592282
Background: One in 10 patients with hyperuricemia may develop gout over time, with urate deposition sometimes asymptomatic. Recent reviews and guidelines support ultrasound (US) to assess asymptomatic hyperuricemic (AH) patients...
3.
Plasencia-Rodriguez C, Martinez-Feito A, Novella-Navarro M, de Diego R, Bonilla G, Gehin J, et al.
Front Med (Lausanne)
. 2024 Sep;
11:1461396.
PMID: 39296891
Background: The EXXELERATE study revealed poorer clinical outcomes in patients treated with adalimumab (ADL) and baseline rheumatoid factor (RF) above 203 IU/mL. However, responses were similar in patients treated with...
4.
Villalba A, Nuno L, Benito-Miguel M, Nieto-Carvalhal B, Monjo I, Novella-Navarro M, et al.
Rheumatology (Oxford)
. 2024 Aug;
PMID: 39141491
Objectives: A subset of human circulating FoxP3+ regulatory T cells expresses CD39 (cTreg39+) and hydrolyses pro-inflammatory adenine nucleotides released at inflammatory foci, rendering the anti-inflammatory agent adenosine. Methotrexate (MTX), inhibiting...
5.
Novella-Navarro M, Ruiz-Esquide V, Lopez-Juanes N, Chacur C, Monjo-Henry I, Nuno L, et al.
Clin Rheumatol
. 2024 Jul;
43(9):2817-2823.
PMID: 39009920
Objectives: To evaluate the survival of different biologic or targeted-synthetic disease-modifying antirheumatic drugs (b/tsDMARD) administered after fulfilling difficult-to-treat rheumatoid arthritis (D2TRA) criteria, and to assess factors related to treatment discontinuation....
6.
Fernandez-Fernandez E, Brugarolas E, Monjo-Henry I, Novella-Navarro M, Balsa A, De Miguel E
Rheumatology (Oxford)
. 2024 May;
64(3):1459-1463.
PMID: 38759208
Objectives: To investigate whether hypoechoic wall thickness is influenced by the systole or diastole moment in the cardiac cycle and if this can influence US assessments of GCA. Methods: US...
7.
Novella-Navarro M, Iniesta-Chamorro J, Benavent D, Bachiller-Corral J, Calvo-Aranda E, Borrell H, et al.
JMIR Res Protoc
. 2024 Mar;
13:e55829.
PMID: 38501508
Background: Rheumatic and musculoskeletal diseases (RMDs) are chronic diseases that may alternate between asymptomatic periods and flares. These conditions require complex treatments and close monitoring by rheumatologists to mitigate their...
8.
Martinez-Feito A, Plasencia-Rodriguez C, Novella-Navarro M, Gehin J, Hernandez-Breijo B, Brenis C, et al.
Clin Exp Rheumatol
. 2024 Jan;
42(5):999-1005.
PMID: 38197184
Objectives: Certolizumab pegol (CZP), an Fc-free antibody fragment, has shown stable serum levels and steady efficacy in the treatment of RA patients, irrespective of RF levels at baseline. Here, we...
9.
Martinez-Feito A, Novella-Navarro M, Hernandez-Breijo B, Nozal P, Peiteado D, Villalba A, et al.
Rheumatology (Oxford)
. 2024 Jan;
64(1):344-351.
PMID: 38175741
Objectives: To investigate the appearance of anti-drug antibodies (ADA) against infliximab (IFX) determined by drug-sensitive and drug-tolerant assays and their relationship with drug levels and drug survival. Methods: This longitudinal...
10.
Valdivieso Shephard J, Alvarez Robles E, Camara Hijon C, Hernandez Breijo B, Novella-Navarro M, Bogas Schay P, et al.
Heliyon
. 2024 Jan;
10(1):e22925.
PMID: 38163219
Introduction: Rheumatoid arthritis (RA) is a heterogeneous disease in which therapeutic strategies used have evolved dramatically. Despite significant progress in treatment strategies such as the development of anti-TNF drugs, it...